Gastroresistant microparticles containing sodium alendronate prevent the bone loss in ovariectomized rats.

[1]  S. Guterres,et al.  Microencapsulation of sodium alendronate reduces drug mucosal damage in rats , 2010, Drug delivery.

[2]  S. Guterres,et al.  HIGH ENCAPSULATION EFFICIENCY OF SODIUM ALENDRONATE IN EUDRAGIT S100/HPMC BLEND MICROPARTICLES , 2009 .

[3]  S. Guterres,et al.  Increasing sodium pantoprazole photostability by microencapsulation: effect of the polymer and the preparation technique. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[4]  R. Handa,et al.  Postovariectomy weight gain in female rats is reversed by estrogen receptor alpha agonist, propylpyrazoletriol. , 2008, American journal of obstetrics and gynecology.

[5]  C. Franceschi,et al.  Calcium metabolism and vitamin D in the extreme longevity , 2008, Experimental Gerontology.

[6]  E. Jäger,et al.  Rate-modulating PHBHV/PCL microparticles containing weak acid model drugs. , 2007, International journal of pharmaceutics.

[7]  S. Haas,et al.  Development of HPMC and Eudragit S100 blended microparticles containing sodium pantoprazole. , 2007, Die Pharmazie.

[8]  S. Guterres,et al.  Microparticles prepared with poly(hydroxybutyrate-co-hydroxyvalerate) and poly(ε-caprolactone) blends to control the release of a drug model , 2007, Journal of microencapsulation.

[9]  S. Guterres,et al.  Pantoprazole-loaded Eudragit blended microparticles: preparation, characterization, in vitro gastro-resistance and in vivo anti-ulcer evaluation , 2007 .

[10]  N. D. da Silveira,et al.  Physico-chemical characterization and in vivo evaluation of indomethacin ethyl ester-loaded nanocapsules by PCS, TEM, SAXS, interfacial alkaline hydrolysis and antiedematogenic activity. , 2006, Journal of nanoscience and nanotechnology.

[11]  S. Guterres,et al.  Preparation, characterization, and in vivo anti-ulcer evaluation of pantoprazole-loaded microparticles. , 2006, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[12]  E. Comunello,et al.  Antiulcerogenic Activity of Crude Extract, Fractions and Populnoic Acid Isolated from Austroplenckia populnea (Celastraceae) , 2006, Zeitschrift fur Naturforschung. C, Journal of biosciences.

[13]  N. D. da Silveira,et al.  Diffusion and mathematical modeling of release profiles from nanocarriers. , 2006, International journal of pharmaceutics.

[14]  J. Cramer,et al.  Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis* , 2005, Current medical research and opinion.

[15]  Matthew Roberts,et al.  The use of hypromellose in oral drug delivery , 2005, The Journal of pharmacy and pharmacology.

[16]  Hyun Jin Park,et al.  Encapsulation of vitamin C in tripolyphosphate cross-linked chitosan microspheres by spray drying , 2005, Journal of microencapsulation.

[17]  D. Kendler,et al.  Pharmaceutical care and community pharmacists’ understanding of bisphosphonate dosing information 1 , 2004, Journal of clinical pharmacy and therapeutics.

[18]  I. Hamdan,et al.  Spectroscopic and HPLC methods for the determination of alendronate in tablets and urine. , 2004, Talanta.

[19]  X. Zhu,et al.  Polymer microspheres for controlled drug release. , 2004, International journal of pharmaceutics.

[20]  F. Pérez-López,et al.  Postmenopausal osteoporosis and alendronate. , 2004, Maturitas.

[21]  Mahaveer D. Kurkuri,et al.  Poly(vinyl alcohol) and poly(acrylic acid) sequential interpenetrating network pH-sensitive microspheres for the delivery of diclofenac sodium to the intestine. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[22]  K. Nas,et al.  Gastrointestinal side effect profile due to the use of alendronate in the treatment of osteoporosis. , 2003, Yonsei medical journal.

[23]  P. Lakatos,et al.  Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis. , 2003, Endocrine regulations.

[24]  B. Ettinger,et al.  Early discontinuation of treatment for osteoporosis. , 2003, The American journal of medicine.

[25]  T. Iguchi,et al.  Multiple mechanisms are involved in apoptotic cell death in the mouse uterus and vagina after ovariectomy. , 2003, Reproductive toxicology.

[26]  C. Nastruzzi,et al.  Spray dried Eudragit microparticles as encapsulation devices for vitamin C. , 2002, International journal of pharmaceutics.

[27]  D. Baker.  Alendronate and risedronate: what you need to know about their upper gastrointestinal tract toxicity. , 2002, Reviews in gastroenterological disorders.

[28]  N A Peppas,et al.  Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). , 2001, Advanced drug delivery reviews.

[29]  W. Jee,et al.  Overview: animal models of osteopenia and osteoporosis. , 2001, Journal of musculoskeletal & neuronal interactions.

[30]  G. Mundy.  Pathogenesis of osteoporosis and challenges for drug delivery. , 2000, Advanced drug delivery reviews.

[31]  S. Martelli,et al.  Polymers with pH-Dependent Solubility: Possibility of Use in the Formulation of Gastroresistant and Controlled-Release Matrix Tablets , 2000, Drug development and industrial pharmacy.

[32]  P. Delmas.  Markers of Bone Turnover for Monitoring Treatment of Osteoporosis with Antiresorptive Drugs , 2000, Osteoporosis International.

[33]  J. Ford,et al.  Thermal analysis of hydroxypropylmethylcellulose and methylcellulose: powders, gels and matrix tablets. , 1999, International journal of pharmaceutics.

[34]  F. Castelli,et al.  Comparative study of 'in vitro' release of anti-inflammatory drugs from polylactide-co-glycolide microspheres , 1998 .

[35]  D. Felsenberg,et al.  Placebo-controlled multicenter study of oral alendronate in postmenopausal osteoporotic women. FOSIT-Study-Group. Fosamax International Trial. , 1998, Maturitas.

[36]  H. Ammar,et al.  Preparation and Evaluation of Sustained-Release Solid Dispersions of Drugs with Eudragit Polymers , 1997 .

[37]  P. Geusens,et al.  Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. , 1996, Bone.

[38]  N. Peppas.  Analysis of Fickian and non-Fickian drug release from polymers. , 1985, Pharmaceutica acta Helvetiae.

[39]  N. Peppas,et al.  Mechanisms of solute release from porous hydrophilic polymers , 1983 .